[1]
|
Blank CU, Haining WN, Held W, et al. Defining ‘T cell exhaustion’[J]. Nat Rev Immunol, 2019, 19(11):665-674. doi: 10.1038/s41577-019-0221-9
|
[2]
|
Choi BD, Maus MV, June CH, et al. Immunotherapy for glioblastoma: adoptive T-cell strategies[J]. Clin Cancer Res, 2019, 25(7):2042-2048.
|
[3]
|
Mandriani B, Pelle' E, Pezzicoli G, et al. Adoptive T-cell immunotherapy in digestive tract malignancies: current challenges and future perspectives[J]. Cancer Treat Rev, 2021, 100:102288. doi: 10.1016/j.ctrv.2021.102288
|
[4]
|
Lowery FJ, Krishna S, Yossef R, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers[J]. Science, 2022, 375(6583):877-884.
|
[5]
|
Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer[J]. Science, 2015, 348(6230):62-68. doi: 10.1126/science.aaa4967
|
[6]
|
Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains[J]. Nat Rev Clin Oncol, 2021, 18(11):715-727. doi: 10.1038/s41571-021-00530-z
|
[7]
|
Zhang ZC, Miao LL, Ren ZJ, et al. Gene-edited interleukin CAR-T cells therapy in the treatment of malignancies: present and future[J]. Front Immunol, 2021, 12:718686.
|
[8]
|
Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing[J]. Mol Cancer, 2022, 21(1):78. doi: 10.1186/s12943-022-01559-z
|
[9]
|
D'Angelo SP, Melchiori L, Merchant MS, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma[J]. Cancer Discov, 2018, 8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417
|
[10]
|
Park S, Ock CY, Kim H, et al. Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer[J]. J Clin Oncol, 2022:JCO2102010. doi: 10.1200/JCO.21.02010
|
[11]
|
Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update[J]. Cancer Immunol Immunother, 2005, 54(3):187-207. doi: 10.1007/s00262-004-0560-6
|
[12]
|
Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J]. Nat Med, 2021, 27(8):1410-1418. doi: 10.1038/s41591-021-01462-y
|
[13]
|
Feng KC, Guo YL, Dai HR, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer[J]. Sci China Life Sci, 2016, 59(5):468-479. doi: 10.1007/s11427-016-5023-8
|
[14]
|
Zhang YJ, Zhang ZW, Ding YM, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients[J]. J Cancer Res Clin Oncol, 2021, 147(12):3725-3734. doi: 10.1007/s00432-021-03613-7
|
[15]
|
Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J]. Mol Ther, 2010, 18(4):843-851. doi: 10.1038/mt.2010.24
|
[16]
|
Kachala SS, Bograd AJ, Villena-Vargas J, et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma[J]. Clin Cancer Res, 2014, 20(4):1020-1028. doi: 10.1158/1078-0432.CCR-13-1862
|
[17]
|
Wei XR, Lai YX, Li J, et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells[J]. Oncoimmunology, 2017, 6(3):e1284722. doi: 10.1080/2162402X.2017.1284722
|
[18]
|
Gjerstorff MF, Pøhl M, Olsen KE, et al. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma[J]. BMC Cancer, 2013, 13:466. doi: 10.1186/1471-2407-13-466
|
[19]
|
Xia Y, Tian XP, Wang JT, et al. Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: a case report[J]. Oncol Lett, 2018, 16(6):6998-7007.
|
[20]
|
Parker KR, Migliorini D, Perkey E, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies[J]. Cell, 2020, 183(1):126-142. doi: 10.1016/j.cell.2020.08.022
|
[21]
|
Manfredi F, Cianciotti BC, Potenza A, et al. TCR redirected T cells for cancer treatment: achievements, hurdles, and goals[J]. Front Immunol, 2020, 11:1689. doi: 10.3389/fimmu.2020.01689
|